The Clinical Outcomes of Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Nationwide Registry Study of the Korean Multiple Myeloma Working Party (KMMWP)

被引：0
|
作者：
Lee, Ho Sup
Min, Chang-Ki
Lee, Je-Jung
Kim, Kihyun
Yoon, Sung-Soo
Kim, Inho
Bang, Soo-Mee
Kim, Jin Seok
Eom, Hyeon-Seok
Yoon, Dok Hyun
Lee, Yoojin
Shin, Ho-Jin
Park, Yong
Jo, Jae-Cheol
Lee, Won-Sik
Do, Young Rok
Mun, Yeung-Chul
Lee, Mark Hong
Kim, Hyo Jung
Kim, Sung-Hyun
Kim, Min Kyoung
Lim, Sung-Nam
Cho, Su-Hee
Park, Seong Kyu
Lee, Joon-ho
Lee, Jae Hoon
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3130
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma
    Richter, Joshua R.
    Bilotti, Elizabeth
    McBride, Laura
    Schmidt, Linda
    Gao, Zhijie
    Tufail, Madiha
    Anand, Palka
    McNeill, Ann
    Bednarz, Urszula
    Graef, Thorsten
    Vesole, David H.
    Siegel, David S.
    BLOOD, 2011, 118 (21) : 1706 - 1706
  • [42] Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone
    San-Miguel, Jesus F.
    Dimopoulos, Meletios A.
    Stadtmauer, Edward A.
    Rajkumar, S. Vincent
    Siegel, David
    Bravo, Marie-Laure
    Olesnyckyj, Marta
    Knight, Robert D.
    Zeldis, Jerome B.
    Harousseau, Jean-Luc
    Weber, Donna M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (01): : 38 - 43
  • [43] Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma
    Ji Hyun Lee
    Sung-Hyun Kim
    Hye Ryeon Kim
    Chang-Ki Min
    Je-Jung Lee
    Ho-Jin Shin
    Jae-Cheol Jo
    Ji Yun Lee
    Joon Ho Moon
    Kihyun Kim
    International Journal of Hematology, 2023, 117 : 225 - 235
  • [44] Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma
    Lee, Ji Hyun
    Kim, Sung-Hyun
    Kim, Hye Ryeon
    Min, Chang-Ki
    Lee, Je-Jung
    Shin, Ho-Jin
    Jo, Jae-Cheol
    Lee, Ji Yun
    Moon, Joon Ho
    Kim, Kihyun
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (02) : 225 - 235
  • [45] Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies
    Maisnar, V.
    Stefanikova, Z.
    Spicka, I.
    Pour, L.
    Minarik, J.
    Flochova, M.
    Radocha, J.
    Gregora, E.
    Stecova, N.
    Jelinek, T.
    Jungova, A.
    Kralikova, E.
    Brozova, L.
    Hajek, R.
    NEOPLASMA, 2019, 66 (03) : 499 - 505
  • [46] Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone
    Shin, Junghoon
    Lee, Je-Jung
    Kim, Kihyun
    Min, Chang-Ki
    Lee, Jeong-Ok
    Suh, Cheolwon
    Kim, Jin Seok
    Lee, Yoo Jin
    Yoon, Sung-Soo
    Jo, Jae-Cheol
    Lee, Ho Sup
    Bang, Soo-Mee
    Lee, Jeong-Ok
    Bang, Soo-Mee
    Lee, Je-Jung
    Kim, Kihyun
    Min, Chang-Ki
    Suh, Cheolwon
    Yoon, Dok Hyun
    Kim, Jin Seok
    Lee, Yoo Jin
    Moon, Joon Ho
    Yoon, Sung-Soo
    Kim, Inho
    Jo, Jae-Cheol
    Lee, Ho Sup
    Park, Seong Kyu
    Shin, Ho-Jin
    Kim, Min Kyoung
    Mun, Yeung-Chul
    Lee, Mark Hong
    Park, Yong
    Eom, Hyeon Seok
    Kim, Hyo Jung
    Im, Sung Nam
    Kim, Sung-Hyun
    Do, Young Rok
    Lee, Won Sik
    Cho, Su-Hee
    Yi, Jun Ho
    Lee, Jae Hoon
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (01) : 79 - 90
  • [47] Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone
    Junghoon Shin
    Je-Jung Lee
    Kihyun Kim
    Chang-Ki Min
    Jeong-Ok Lee
    Cheolwon Suh
    Jin Seok Kim
    Yoo Jin Lee
    Sung-Soo Yoon
    Jae-Cheol Jo
    Ho Sup Lee
    Soo-Mee Bang
    International Journal of Hematology, 2019, 109 : 79 - 90
  • [48] Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
    Siegel, David S.
    Dimopoulos, Meletios A.
    Ludwig, Heinz
    Facon, Thierry
    Goldschmidt, Hartmut
    Jakubowiak, Andrzej
    San-Miguel, Jesus
    Obreja, Mihaela
    Blaedel, Julie
    Stewart, A. Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) : 728 - +
  • [49] Erratum to: Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma
    Shinsuke Iida
    Takaaki Chou
    Shinichiro Okamoto
    Hirokazu Nagai
    Kiyohiko Hatake
    Hirokazu Murakami
    Toshiyuki Takagi
    Kazuyuki Shimizu
    Henry Lau
    Kenichi Takeshita
    Masaaki Takatoku
    Tomomitsu Hotta
    International Journal of Hematology, 2010, 92 (1) : 127 - 128
  • [50] Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)
    Lacy, Martha Q.
    LaPlant, Betsy R.
    Laumann, Kristina M.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Ailawadhi, Sikander
    Chanan-Khan, Asher
    Stewart, A. Keith
    Reeder, Craig B.
    Rajkumar, S. Vincent
    Mikhael, Joseph R.
    BLOOD, 2014, 124 (21)
12345